NASH/NAFLD | MediciNova, Inc.

2023.08.14 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

MN-001NASH/NAFLDpatents

2022.07.26 MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MN-001NASH/NAFLD

2022.04.11 MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

MN-001NASH/NAFLD

2022.03.17 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea

MN-001NASH/NAFLDpatents

2021.11.12 MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

MN-001NASH/NAFLDacademic conference

2021.09.01 MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

MN-001NASH/NAFLDacademic conference

2020.02.18 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan

MN-001NASH/NAFLDpatents

2019.10.23 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan

MN-001NASH/NAFLDpatents

2019.03.06 東京慈恵会医科大学との共同研究開始のお知らせ

MN-001NASH/NAFLDjoint research

2018.06.20 MN-001の高中性脂肪血症、高コレステロール血症及び高リポタンパク血症を適応とする日本における特許承認のお知らせ

MN-001NASH/NAFLDpatents

2018.04.13 国際肝臓会議2018/第53回欧州連合肝臓研究会年次総会におけるMN-001のNASH/NAFLDを適応とするフェーズ2臨床治験の中間解析に関するポジティブデータ発表のお知らせ

MN-001NASH/NAFLDacademic conference

2018.04.02 MN-001の高中性脂肪血症を伴うNASH /NAFLDを適応とするフェーズ2臨床治験の早期終了のお知らせ－中間解析における極めて良好な結果を踏まえて－